AstraZeneca PLC has released its final results for the fiscal year (FY) 2025, showcasing strong commercial performance and pipeline delivery. Here’s a summary of the key highlights
### **Financial Performance**
**Total Revenue**Increased by 8% to $58,739 million, driven by growth in Oncology, Cardiovascular, Renal & Metabolism (CVRM), Respiratory & Immunology (R&I), and Rare Disease segments.
**Core EPS**: Grew by 11% to $9.16with Reported EPS at $6.60.
**Dividends**Second interim dividend declared at $2.17 per share, with a total FY 2025 dividend of $3.20 per share, up 3%.
### **Pipeline and Regulatory Milestones**
**Phase 3 Readouts**16 positive Phase 3 readouts in the last 12 months.
**Approvals**43 approvals in major regions, including Enhertu, Imfinzi, and Saphnelo.
**Ongoing Trials**Over 100 Phase 3 studies, including transformative technologies with potential to revolutionize patient outcomes.
### **Strategic Developments**
**NYSE Listing**Ordinary shares began trading on the NYSE on February 2, 2026, harmonizing listings across London, New York, and Stockholm.
**China Investment**Announced $15 billion investment in China through 2030 for manufacturing and R&D expansion.
**Acquisitions and Collaborations**
Acquired Modella AI to enhance oncology R&D with AI.
Strategic collaboration with CSPC Pharmaceuticals for weight management portfolio.
Acquired AbelZeta’s 50% share in C-CAR031 for global development.
### **Sustainability**
Recognized by CDP for climate action and water stewardship, with an A for Climate and A- for Water Security.
Launched PSA 2090, a global standard to measure environmental impact of pharmaceutical products.
### **Guidance for FY 2026**
**Total Revenue**Expected to increase by mid-to-high single-digit percentage.
**Core EPS**Expected to increase by a low double-digit percentage.
**Core Tax Rate**Projected between 18-22%.
### **Key Medicines Performance**
**Oncology**: TagrissoImfinziand Enhertu showed strong growth.
**CVRM**: Farxiga led growthdriven by HF and CKD indications.
**R&I**Fasenra and Tezspire demonstrated sustained demand growth.
**Rare Disease**Ultomiris and Soliris saw growth, with Soliris declining due to patient conversion to Ultomiris.
### **Corporate and Business Development**
**Jacobio Pharma**Exclusive rights for JAB-23E73 outside China.
**BMS**Paid $170 million to reduce royalties on Saphnelo sales ex-US.
**Compugen**Paid $65 million for a portion of royalty interest in rilvegostomig.
### **Sustainability and Health Equity**
Expanded Healthy Heart Africa program to include CKD screening in multiple African countries.
Committed to China’s rare disease ecosystem and global health equity initiatives.
### **Outlook**
AstraZeneca anticipates continued momentum in 2026, with over 20 Phase 3 trial readouts expected. The company remains focused on transformative technologies and sustainable growth, aiming to drive long-term value for patients and shareholders.
For more details, refer to the full report on the London Stock Exchanges RNS platform.
